Human Longevity Inc. (HLI), a leader in precision medicine, has announced the completion of an upsized $39.8 million Series B financing round. The company intends to use the funds to further develop its cutting-edge 100% precision longevity care program.
The Series B round was led by several prominent investors, enabling HLI to enhance its technology and expand its medical and wellness offerings. The company’s precision care program focuses on personalized health and longevity solutions, leveraging genomic data, advanced diagnostics, and AI-driven insights to optimize health outcomes.
HLI’s program is designed to provide individuals with a comprehensive understanding of their biology, enabling tailored health strategies to address aging-related conditions and extend healthy lifespan. The funding will also support HLI’s expansion into new markets and increase access to its services.
With this latest funding, Human Longevity Inc. is poised to continue its efforts in transforming the future of personalized healthcare, setting a new standard for precision longevity.
